Globe Newswire (Thu, 9-Jul 4:20 PM ET)
Results of the Votes of the Combined Shareholders' General Meeting of June 30, 2026
Globe Newswire (Thu, 2-Jul 4:00 PM ET)
Claret Capital Partners participates in EUR 130m financing for Inventiva
Globe Newswire (Tue, 16-Jun 5:12 AM ET)
Globe Newswire (Tue, 16-Jun 4:52 AM ET)
Globe Newswire (Fri, 12-Jun 4:00 PM ET)
Combined General Meeting of June 30, 2026 - Availability of the Preparatory Documents
Globe Newswire (Tue, 9-Jun 4:00 PM ET)
Inventiva Announces Trading Resumption of its Ordinary Shares on Euronext Paris
Globe Newswire (Tue, 2-Jun 8:30 AM ET)
Globe Newswire (Tue, 2-Jun 8:29 AM ET)
Inventiva Announces Temporary Trading Halt of its Ordinary Shares on Euronext Paris
Globe Newswire (Tue, 2-Jun 1:30 AM ET)
Inventiva Reports 2026 First Quarter Financial Information
Globe Newswire (Tue, 26-May 4:00 PM ET)
Inventiva SA is a France-based clinical-stage biopharmaceutical company focused on the development of oral small-molecule therapies for the treatment of MASH. The wholly-owned research and development facility and a team with expertise and experience in the development of compounds that target nuclear receptors, transcription factors and epigenetic modulation. Leveraging the expertise, the company is also advancing lanifibranor for the treatment of MASH and has a pipeline of earlier-stage therapeutic programs in oncology. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France.
Inventiva S.A. - American Depository Shares trades on the NASDAQ stock market under the symbol IVA.
As of July 16, 2026, IVA stock price declined to $4.43 with 346,772 million shares trading.
IVA has a beta of 1.68, meaning it tends to be more sensitive to market movements. IVA has a correlation of 0.05 to the broad based SPY ETF.
IVA has a market cap of $1.05 billion. This is considered a Small Cap stock.
Last quarter Inventiva S.A. - American Depository Shares reported $5 million in Revenue and -$2.14 earnings per share. This fell short of revenue expectation by $-936,000 and missed earnings estimates by -$.48.
In the last 3 years, IVA traded as high as $7.98 and as low as $1.53.
The top ETF exchange traded funds that IVA belongs to (by Net Assets): MEDI, APIE.
IVA has outperformed the market in the last year with a price return of +33.0% while the SPY ETF gained +22.1%. However, in the short term, IVA had mixed performance relative to the market. It has underperformed in the last 3 months, returning -22.8% vs +7.7% return in SPY. But in the last 2 weeks, IVA shares have fared better than the market returning +20.1% compared to SPY +0.8%.
IVA support price is $4.26 and resistance is $4.68 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that IVA shares will trade within this expected range on the day.